HQY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HQY is a good buy right now for a beginner with a long-term focus and $50,000-$100,000 to invest. The stock is showing constructive pre-market strength near 92 after a strong Q1 beat, raised fiscal 2027 guidance, and a larger buyback plan. Analyst sentiment is mostly positive with multiple Buy/Outperform ratings and higher targets, while the option market also leans bullish. Given the recent operational momentum and favorable long-term story, I would buy it now rather than wait for a lower entry.
HQY's trend is positive. The MACD histogram is above zero and expanding, which supports upside momentum. RSI_6 is 75.569, showing the stock is extended but not giving a clear reversal signal in the provided data. Moving averages are converging, suggesting the stock may be stabilizing after a move higher. Price is trading around 90.52 in the option data and 92 pre-market, which is above the pivot at 86.047 and close to resistance at 90.004 and 92.449. That means momentum is favorable, but the stock is entering resistance territory. The short-term pattern statistics suggest only modest near-term upside, but the broader trend remains constructive.
["Q1 revenue grew 7.2% year over year to $354.6 million.", "Non-GAAP EPS of $1.24 beat expectations.", "Fiscal 2027 revenue guidance was raised.", "Share buyback plan increased by $1 billion.", "Service revenue reached a record $122.9 million.", "Analysts highlighted a new large, high-margin growth opportunity from the Marketplace launch.", "Long-term HSA market expansion remains a tailwind."]
["Hedge funds are selling, with selling increasing 213.73% over the last quarter.", "RSI is elevated, suggesting the stock is somewhat stretched after recent strength.", "The stock is near resistance levels around 90.00 to 92.45.", "Short-term pattern data shows only modest near-term upside."]
Latest quarter shown is Q1. HealthEquity delivered strong Q1 results with revenue of $354.6 million, up 7.2% year over year, and non-GAAP EPS of $1.24, which beat estimates. Service revenue hit a record $122.9 million. The company also raised fiscal 2027 revenue guidance and increased its buyback authorization by $1 billion, which points to improving growth visibility and shareholder returns.
Analyst sentiment has improved overall. BMO upgraded HQY to Outperform with a $105 target, saying concerns about AI disruption are overblown and that the Marketplace launch could create a large, high-margin growth opportunity. Deutsche Bank raised its target to $128 and kept Buy. Barrington, JPMorgan, and RBC all kept bullish ratings, though some trimmed targets slightly after the Q4 report. Overall, Wall Street remains constructive, with the pros focused on execution, HSA market expansion, guidance raises, and platform growth.
